Vaccinex Inc. [NASDAQ: VCNX] slipped around -0.37 points on Friday, while shares priced at $3.08 at the close of the session, down -10.72%. The company report on January 5, 2021 that Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event.
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.
Maurice Zauderer, Ph.D., President and CEO, will host 1×1 meetings and will present a corporate update on Wednesday, January 6th at 11am EST.
Vaccinex Inc. stock is now 48.79% up from its year-to-date (YTD) trading value. VCNX Stock saw the intraday high of $3.35 and lowest of $2.96 per share. The company’s 52-week high price is 9.40, which means current price is +50.98% above from all time high which was touched on 02/04/21.
Compared to the average trading volume of 745.78K shares, VCNX reached a trading volume of 1445370 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vaccinex Inc. [VCNX]?
BTIG Research have made an estimate for Vaccinex Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 23, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 04, 2018, representing the official price target for Vaccinex Inc. stock.
The Average True Range (ATR) for Vaccinex Inc. is set at 0.28, with the Price to Sales ratio for VCNX stock in the period of the last 12 months amounting to 128.64.
How has VCNX stock performed recently?
Vaccinex Inc. [VCNX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.51. With this latest performance, VCNX shares gained by 46.67% in over the last four-week period, additionally sinking by -52.25% over the last 6 months – not to mention a drop of -52.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VCNX stock in for the last two-week period is set at 62.24, with the RSI for the last a single of trading hit 62.63, and the three-weeks RSI is set at 60.96 for Vaccinex Inc. [VCNX]. The present Moving Average for the last 50 days of trading for this stock 2.32, while it was recorded at 2.95 for the last single week of trading, and 3.49 for the last 200 days.
Vaccinex Inc. [VCNX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vaccinex Inc. [VCNX] shares currently have an operating margin of -6121.41 and a Gross Margin at +14.34. Vaccinex Inc.’s Net Margin is presently recorded at -6092.35.
Reflecting on the efficiency of the workforce at the company, Vaccinex Inc. [VCNX] managed to generate an average of -$650,265 per employee. Receivables Turnover for the company is 0.68 with a Total Asset Turnover recorded at a value of 0.04.Vaccinex Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.30.
Earnings analysis for Vaccinex Inc. [VCNX]
With the latest financial reports released by the company, Vaccinex Inc. posted -0.38/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VCNX.
Insider trade positions for Vaccinex Inc. [VCNX]
There are presently around $1 million, or 50.30% of VCNX stock, in the hands of institutional investors. The top three institutional holders of VCNX stocks are: VANGUARD GROUP INC with ownership of 142,297, which is approximately 2.892% of the company’s market cap and around 0.30% of the total institutional ownership; TELEMETRY INVESTMENTS, L.L.C., holding 58,300 shares of the stock with an approximate value of $0.18 million in VCNX stocks shares; and CITADEL ADVISORS LLC, currently with $0.14 million in VCNX stock with ownership of nearly New of the company’s market capitalization.
Positions in Vaccinex Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 15 institutional holders increased their position in Vaccinex Inc. [NASDAQ:VCNX] by around 250,710 shares. Additionally, 9 investors decreased positions by around 1,000,851 shares, while 3 investors held positions by with 798,246 shares. The mentioned changes placed institutional holdings at 453,315 shares, according to the latest SEC report filing. VCNX stock had 8 new institutional investments in for a total of 234,838 shares, while 7 institutional investors sold positions of 971,680 shares during the same period.